|
Left to Right:
Dr. Douglas Cines, Dr. Garrett Bergman, Joan Young and Dennis Jackman
About the Participants
Douglas B. Cines, M.D.
Dr. Douglas B. Cines is a board-certified hematologist, professor of pathology and vice-chair for academics in the Department of Pathology and Laboratory Medicine at the Hospital of the University of Pennsylvania (HUP). He is also the director of the Hematology Laboratory and the Coagulation Laboratory at HUP. Dr. Cines has published more than 139 peer-reviewed articles, received numerous grants and holds several patents. He is also a member of several professional and honorary societies. Dr. Cines holds a doctorate in medicine from New York University School of Medicine.
Garrett E. Bergman, M.D.
Dr. Garrett E. Bergman is senior director of U.S. Medical Affairs at CSL Behring. After a distinguished academic career in medicine, Dr. Bergman has been working in the biopharmaceutical industry, in research and development and medical affairs, since 1987. Dr. Bergman served at Rhone Poulenc Rorer and at Armour, which merged with Behringwerke AG to become Centeon LLC — a predecessor company of CSL Behring. Most recently, Dr. Bergman was vice president, Research and Development, at Octagen Corporation.
Dr. Bergman holds a doctorate in medicine from Jefferson Medical College and a master’s degree in business administration from Temple University School of Business and Management.
Joan Young
Joan Young is president and founder of the Platelet Disorder Support Association (PDSA). Founded in 1998, PDSA is a non-profit organization providing information and support services, while also encouraging research about ITP and other platelet disorders.
The roots of PDSA’s founding trace back to 1997 when Ms. Young began a Website that provided a place to share ITP stories — including her own. PDSA was created as a result. Today thousands of people come to the organization. Besides patient education, support services and public education, PDSA encourages research in the treatment of ITP and other platelet disorders through surveys and collaboration with the National Institutes of Health, physicians and researchers. The organization has a global reach; fifteen percent of the 24,000 people on the mailing list live outside the U.S.
Dennis Jackman
Dennis Jackman is senior vice president of Public Affairs at CSL Behring. Mr. Jackman is responsible for optimizing stakeholder impact on CSL Behring’s ability to provide lifesaving therapies worldwide. Previously he served as Executive Director of the Plasma Protein Therapeutics Association for North America, the industry group for advocacy, quality standards and communications. He has held senior public affairs positions in the pharmaceutical and biotechnology industries since 1989. Previously, he was senior legislative aide to U.S. Senator Arlen Specter of Pennsylvania, focusing on pharmaceutical, trade and tax policy.
About CSL Behring
CSL Behring is a global leader in plasma protein biotherapeutics. Dedicated to saving lives and improving the quality of life for patients with rare diseases worldwide, the company provides safe and effective plasma-derived and recombinant products and offers patients a wide range of related services.
Return to Top
Previous:
The Power of Partnership
|